The MEK1/2 kinases have been attractive targets for cancer therapy especially for cancers associated with aberrant activation of the RAS-RAF-MEK-ERK pathway, including melanomas and non–small cell lung cancer (NSCLC; ref. 35). This evidence concerns the gene MAP2K1 and lung cancer.